title: Impact of medical comorbidity on the quality of schizophrenia pharmacotherapy in a national VA sample.
abstract: BACKGROUND
  More than half of patients with schizophrenia have comorbid chronic medical illness. During the past decade, several studies have evaluated the quality of the medical treatment of these conditions. This work examines the impact of comorbid medical conditions on the quality of schizophrenia pharmacotherapy in the Department of Veterans Affairs (VA).
  
  
  METHODS
  Data for this study came from national VA administrative databases. All VA outpatients diagnosed with schizophrenia during fiscal year 2002 were identified, and the presence of 9 chronic medical conditions was determined by ICD-9 codes. Measures of quality of schizophrenia pharmacotherapy were based on the Schizophrenia Patient Outcomes Research Team (PORT) and included the proportion of patients who received any antipsychotic medications, multiple antipsychotic medications, atypical antipsychotic medications, and dosages in compliance with PORT recommendations. Multivariate logistic regression analysis was used to determine the effects of comorbid medical illness on these measures.
  
  
  RESULTS
  Overall, 92.2% of the patients were prescribed an antipsychotic medication. Patients with 6 of the 9 chronic medical conditions were significantly less likely to be prescribed antipsychotic medications, and the odds of this treatment decreased with increasing medical complexity. 63.8% received doses which were within the recommended PORT guidelines.
  
  
  CONCLUSIONS
  In a large national sample of veterans with schizophrenia, several chronic medical conditions were associated with a decreased likelihood of being prescribed an antipsychotic medication, suggesting less intensive schizophrenia treatment. Patients with medical comorbidity who were treated with antipsychotic medications were as likely to receive doses within the PORT guidelines as schizophrenic patients without medical comorbidity.
authors.affiliation: Department of Psychiatry, Yale School of Medicine, New Haven 06519, and Northeast Program Evaluation Center, VA Connecticut Healthcare System, West Haven, Connecticut, USA. chwastiak@yale.edu
authors.forename: Lydia
authors.initials: L
authors.lastname: Chwastiak
authors.forename: Robert
authors.initials: R
authors.lastname: Rosenheck
authors.forename: Douglas
authors.initials: D
authors.lastname: Leslie
mesh_terms: D000328:Adult; D000368:Aged; D014150:Antipsychotic Agents / Q000008:administration & dosage / Q000627:therapeutic use; D002908:Chronic Disease; D004358:Drug Therapy / Q000592:standards*; D005260:Female; D006801:Humans; D038801:International Classification of Diseases; D008297:Male; D008485:Medical Audit; D008875:Middle Aged; D015999:Multivariate Analysis; D011787:Quality of Health Care; D012044:Regression Analysis; D012559:Schizophrenia / Q000150:complications* / Q000188:drug therapy*; D014481:United States; D014493:United States Department of Veterans Affairs
chemical_list: D014150:Antipsychotic Agents